Bax suppresses tumorigenesis in a mouse model system and Bax-de®cient mice exhibit lymphoid hyperplasia suggesting that BAX functions as a tumour suppressor in human haemopoietic cells. We examined BAX expression in 20 cell lines derived from human haemopoietic malignancies and consistent with a potential tumour suppressor function, identi®ed two cell lines, DG75 (a Burkitt lymphoma cell line) and Jurkat (a T-cell leukaemia line), which lacked detectable BAX expression. Apoptosis of DG75 cells induced by low serum or ionomycin was signi®cantly delayed relative to similar Burkitt lymphoma cell lines with normal BAX levels. Although DG75 and Jurkat cells expressed several BAX RNA species including the prototypical BAX a RNA, the absence of BAX protein was due to single base deletions and additions in a polyguanine tract within the BAX open reading frame. These frameshift mutations result in premature termination of translation and have recently also been identi®ed in some colon cancers with microsatellite instability. Although mismatch repair defects are not considered a common feature of haemopoietic malignancies, DG75 and Jurkat cells had widespread microsatellite instability and did not express detectable levels of MSH2. In Jurkat cells, lack of MSH2 expression was due to a point mutation in exon 13 of MSH2 resulting in premature termination of translation. Our results suggest that a pathway linking mismatch repair defects, BAX tumour suppressor frameshift mutations and resistance to apoptosis may be a key feature of some lymphomas and leukaemias.
Introduction
BAX is a central member of the BCL-2 family of apoptosis regulators since, in addition to homodimerisation, BAX forms heterodimers with several other family proteins, including MCL-1, BCL-X L , A1 and BCL-2 (Oltvai et al., 1993; Sato et al., 1994; Sedlak et al., 1995) . In contrast to its heterotypic partners, BAX overexpression promotes apoptosis (Oltvai et al., 1993; Sakakura et al., 1996; Wagener et al., 1996; Xiang et al., 1996) . BAX suppresses tumorigenesis in a mouse model system by suppressing apoptosis and Baxde®cient mice exhibit lymphoid hyperplasia suggesting that BAX may function as a tumour suppressor in human haemopoietic cells (Knudson et al., 1995; Yin et al., 1997) . In addition to the prototypical BAX a protein, three variant BAX isoforms (BAX b, g d) generated by alternative splicing have been described (Oltvai et al., 1993; Apte et al., 1995) .
The sensitivity of a cell to apoptosis has been proposed to be in¯uenced by the ratio of pro-apoptotic to anti-apoptotic BCL-2 family proteins and downregulation of BAX expression is thought to confer a growth advantage by rendering cells relatively resistant to apoptosis. Alterations in BAX expression consistent with a potential function as a tumour suppressor have been described in human cancers. BAX expression is downregulated in approximately one third of metastatic breast cancers and this correlates with poor prognosis (Krajewski et al., 1995) . BAX missense mutations have also been described in some cell lines derived from human haemopoietic malignancies (Meijerink et al., 1995) . BAX expression has recently been shown to be downregulated in some colon cancers which exhibit microsatellite instability (MI) due to defects in mismatch repair (MMR) (Rampino et al., 1997) . The absence of BAX expression in these tumours is due to insertion or deletion of a single residue in a sequence of eight deoxyguanosine residues ((G)8 tract) within the BAX coding sequence (Rampino et al., 1997) . This alters the reading frame and results in premature termination of translation. However, it is not clear at present if BAX mutations in colon cancer are biologically signi®cant or simply re¯ect MI in these cells.
To examine a possible tumour suppressor role of BAX in human haemopoietic cells, we analysed BAX expression in a panel of cell lines derived from lymphomas and leukaemias. Consistent with a tumour suppressor role, we identi®ed two cell lines lacking BAX. This was due to BAX frameshift mutations and both cell lines with BAX mutations exhibited MI. The MI was associated with MSH2 defects and cells lacking BAX were relatively resistant to apoptosis. These results are consistent with the hypothesis that BAX functions as a tumour suppressor in haemopoietic cells and that loss of BAX expression by frameshift mutations contributes to development of some leukaemias and lymphomas.
Results

BAX is not expressed in some cell lines derived from human haemopoietic malignancies
To search for alterations in BAX expression consistent with a potential tumour suppressor function in haemopoietic cells, we surveyed a panel of cell lines derived from human leukaemias and lymphomas by immunoblotting. We analysed 13 Burkitt lymphoma (BL) derived cell lines, four lines derived from T-cell leukaemia and lymphoma and three cell lines derived from myeloid lineage leukaemia. We also analysed BAX in IB4 and X50-7 cells, lymphoblastoid cell lines (LCL) generated by in vitro immortalisation of human B cells by Epstein ± Barr virus (EBV). The most striking observation was the absence of detectable BAX expression in the EBV negative BL-derived cell line DG75 and the T-cell leukaemia derived cell line Jurkat ( Figure 1a ). This was clearly consistent with a potential tumour suppressor role for BAX in haemopoietic cells.
One possible explanation for the inability to detect BAX expression in DG75 and Jurkat cells was that the epitope recognised by the antibody was mutated. We therefore analysed IB4, DG75 and Jurkat cells using a second BAX speci®c antibody which recognises a distinct epitope. However, similar results were obtained with both antibodies (Figure 1b) . BCL-X L expression was detected in lysates from each cell line demonstrating that equivalent amounts of intact proteins were analysed.
BAX expression was readily detectable in the remaining cell lines (Figure 1a) . The isoform detected was BAX a as it comigrated with the in vitro translation product of the BAX a cDNA (data not shown). We did not detect signi®cant expression of variant BAX isoforms. Expression levels were generally highest in the BL derived cell lines (Figure 1a ). BAX expression in BL cell lines was independent of EBV status and, with the exception of BL72 and WeWakl cells, did not vary more than twofold from the mean level of BAX expression in the BL cell lines. BL72 cells had relatively high BAX expression and WeWakl cells expressed BAX at a level fourfold below the mean expression level. BAX expression was also relatively constant in the T cell and myeloid lineage cell lines and did not vary more than twofold from the mean expression level. The general increase in BAX expression in BL may re¯ect lineage speci®c alterations in levels of BAX expression since BAX expression was also high in LCLs (Figure 1a and data not shown; three further LCLs had expression levels like X50-7 cells). Because the lack of detectable BAX expression was the observation most consistent with a potential tumour suppressor role for BAX, we focused our attention on its mechanism and signi®cance in DG75 and Jurkat cells.
DG75 cells are resistant to apoptosis relative to other EBV negative BL cell lines
To address the consequence of the lack of detectable BAX expression in the cell lines identi®ed, we examined the sensitivity of DG75 cells to apoptosis. We focused on DG75 cells since we could compare them to BL2 and BL41 cells which are EBV negative BL cell lines with normal BAX expression levels ( Figure 1a) and EBV negative BL cell lines are generally very sensitive to cell death induced by serum deprivation or ionomycin Henderson et al., 1991) . This BL cell death is due to apoptosis as it is accompanied by characteristic intranucleosomal fragmentation of genomic DNA resulting in`laddering' and chromatin condensation Henderson et al., 1991) .
DG75, BL2 and BL41 cells were treated with ionomycin or were washed thoroughly to remove serum and resuspended in medium supplemented with 0.1% serum. Cell viability was determined for up to 5 days using trypan blue exclusion as a measure of membrane permeability (Figure 2a and b whereas DG75 and BL41 cells have mutant p53 (Farrell et al., 1991; pers. comm., MJ Allday) .
Resistance to apoptosis of DG75 cells was also independent of BCL-2 as these cells did not express BCL-2 (data not shown) consistent with the lack of BCL-2 expression in BL in vivo (Gala et al., 1994) . There were only modest variations in expression of MCL-1 and BCL-X L cell death antagonists and these variations were unrelated to sensitivity to apoptosis (data not shown). Thus, BAX status in DG75 cells was uniquely correlated with sensitivity to cell death triggered by these conditions. We have not directly studied Jurkat cell death due to the diculty of identifying otherwise comparable cell lines with high BAX expression to use as controls. Although Jurkat cells are sensitive to anti-Fas or staurosporine, they are less sensitive to these agents than CEM-C7 T cells (pers. comm., J Lahti).
To determine whether the delayed cell death of DG75 cells was due to apoptosis or necrosis, we analysed the genomic DNA and morphology of DG75 cells cultured in low serum for 4 days. Consistent with the delayed DG75 cell death being due to apoptosis, we detected weak`laddering' of genomic DNA when DG75 cells were cultured in 0.1%, but not 10% serum ( Figure 2c ). The relatively weak ladder was consistent with the low level of apoptotic cells at any one time. DG75 cells in low serum also exhibited morphological features of apoptosis (Wyllie et al., 1980) , such as membrane blebbing and formation of micronuclei with condensed chromatin (Figure 2d ). Thus, although less sensitive than EBV negative BL cell lines with BAX, DG75 cells retain the ability to undergo apoptosis.
BAX RNA expression in DG75 and Jurkat cells
We next determined the mechanism of downregulation of BAX expression in DG75 and Jurkat cells. Downregulation of BAX expression in human cancer is due to reduced steady state BAX RNA levels in (Krajewski et al., 1995; Bargou et al., 1995) or frameshift mutations in colon cancers (Rampino et al., 1997) . We ®rst analysed BAX RNA in DG75 and Jurkat cells using RNAse protection assays (RPA) which discriminate the alternatively spliced BAX RNAs (Oltvai et al., 1993; Apte et al., 1995) . As a control, we also analysed BAX RNA in IB4 and Namalwa cells which express BAX (Figure 1a ). The structure of the BAX RNAs and the expected protection fragments are shown in Figure 3 . When RNA was analysed by RPA using probe B which hybridizes to the 3' part of BAX RNAs, a major protected fragment of approximately 291 bp and a weaker fragment of approximately 185 bp was obtained with each cell line (Figure 4) . The 291 bp fragment was potentially due to hybridization of the probe to BAX a, g or d RNAs (Figure 3 ) whereas the other fragment was due to hybridization to BAX b RNA. The 106 bp fragment expected for hybridization to BAX b RNA was present but the signal was very weak due to its short length. Similar results were obtained when Namalwa cell RNA was analysed using probe B and BAX b RNA expression was also detected in each cell line when RNAs were analysed by Northern blotting (data not shown).
When IB4 cell RNA was analysed using probe A, which hybridizes to the 5' part of BAX RNAs, we detected a major protected fragment of approximately 233 bp due to hybridization to BAX a RNA (Figure 4) . Therefore, the major BAX RNA in IB4 cells is BAX a. By contrast, when DG75 or Jurkat cell RNA was analysed using probe A, we obtained a dierent protection pattern (Figure 4) . In this case, we detected very low levels of two protection fragments of approximately 115 bp. This pattern of protection is not consistent with hybridization to any of the known BAX RNAs. In addition, we detected very low levels of a 89 bp protection fragment in Jurkat cells due to hybridization to BAX d RNA. Therefore, the lack of detectable BAX expression in DG75 and Jurkat cells was not due to lack of BAX RNA, but the structure of the 5' part of BAX RNA was dierent in these cells. RPA using probe A and other probes mapped this alteration to approximately BAX coding nucleotide 115 (Figure 4 and data not shown).
Frameshift mutation of the BAX gene in DG75 and Jurkat cells BAX frameshift mutations in colon cancers (Rampino et al., 1997) involve the G(8) tract at BAX coding nucleotides 114 ± 121. This is the position we mapped for the BAX RNA structural alterations in DG75 and Jurkat cells, suggesting that the altered RPA protection pattern was due to frameshift mutations in the G(8) tract in these cell lines. Thus, base deletions or Figure 3 Structure of BAX RNAs, riboprobes A and B and their expected protection products. The exon structure of the coding portion of the canonical BAX a RNA (Oltvai et al., 1993 ) is shown at the top, with the structures of riboprobes A and B; boxed sequences are BAX derived sequences and lines are vector derived sequences in each probe. Below is shown the structure of the variant BAX RNAs and the predicted protected fragments for each riboprobe. Striped boxes indicate intron and exon sequences which contribute novel coding information due to lack of splicing of intron 5 (BAX b) or skipping of exon 2 (BAX g). In these RNAs, the new reading frames include stop codons and downstream exons are not translated (open boxes). In BAX d, the novel exon 2/4 splice maintains the BAX reading frame (Apte et al., 1995) insertions would cause probe A to hybridize poorly in this region and be cleaved by RNases. Consistent with this idea, we detected BAX a RNA in DG75 and Jurkat cells by reverse transcription-polymerase chain reaction (RT ± PCR) assay ( Figure 5 ). We also detected BAX g RNA expression in DG75 cells and BAX d RNA was readily detected in Jurkat cells. The relatively high level expression of BAX d and g RNAs detected in the RT ± PCR assay relative to the more quantitative RPA (Figure 4 ) is most likely due to preferential amplification of the smaller cDNAs in this assay.
To determine directly whether BAX frameshift mutations were present in DG75 and Jurkat cells, we isolated genomic DNA from Namalwa, DG75 and Jurkat cells and analysed the (G)8 tract by PCR using BAX exon 3 primers. The PCR products were resolved on a denaturing polyacrylamide gel to detect single base additions and deletions. The PCR product obtained using Namalwa genomic DNA was identical to the 94 bp product obtained by ampli®cation of the wild type BAX a cDNA (Figure 6a and data not shown). By contrast, the DG75 PCR product migrated faster than the wild type product and DG75 cells therefore contain only mutant BAX allele(s) with a deletion within the ampli®ed region. Ampli®cation of Jurkat DNA produced two bands; the faster migrating product comigrated with the DG75 product whereas the slower migrating product was larger than the wild type Namalwa product. Therefore, Jurkat cells contain mutant BAX alleles with deletions or insertions in this region. To con®rm that the mutations were within the G(8) tract, we subcloned and sequenced PCR products spanning this region (Figure 6b ). The single base additions and deletions were identical to those identi®ed in colon cancers with MMR defects (Rampino et al., 1997) .
Analysis of microsatellite instability and MSH2 in DG75 and Jurkat cells BAX frameshift mutations have previously been reported in colon cancers associated with MMR defects (Rampino et al., 1997). Although MI is not thought to be a common feature of haemopoietic malignancies (Gartehnhaus et al., 1996; Larson et al., 1996; Randerson et al., 1996; Robledo et al., 1995; Volpe et al., 1996) , there are clear examples of leukaemia and lymphoma with MI. For example, approximately 50% of human immunode®ciency virus-associated non-Hodgkin's lymphoma and 90% of therapy related leukaemia exhibit instability of at least 25% of markers tested (Bedi et al., 1995; BenYehuda et al., 1996) . These observations prompted us to test whether DG75 and Jurkat cells exhibited MI.
Genomic DNA from DG75 and Jurkat cells was examined for alterations at 35 microsatellite markers distributed throughout the genome. Results for markers 22s315 and 2s340 are shown in Figure 7 . Between 3 and 6 alleles were detected in DG75 and Jurkat cells when these markers were tested. As RT ± PCR analysis of BAX RNA expression. cDNA prepared from the indicated cells was analysed by PCR using BAX speci®c primers T4580 and T4581. The products were detected by hybridization with a radiolabeled BAX speci®c probe. The identity of the ampli®cation products is indicated expected, analysis of the same markers in DNA from normal individuals revealed one or two alleles ( Figure 7) . Overall, clear evidence for instability was observed for at least 25% of markers for both Jurkat and DG75 cells. Therefore, BAX frameshift mutations in DG75 and Jurkat cells are associated with MI. MI is associated with defects in MMR. Since mice lacking MSH2, a key protein required for MMR which is mutated in some hereditary non-polyposis colorectal cancer kindreds (Fishel et al., 1993; Leach et al., 1993; Kolodner et al., 1994; Liu et al., 1994; Kolodner, 1996) , are susceptible to lymphoid tumours (deWind et al., 1995; Reitmar et al., 1995 and MSH2 mutations have recently been described in some human lymphomas (Lowsky et al., 1997) , we analysed MSH2 in DG75 and Jurkat cells by immunoblotting. Although MSH2 was expressed in control cells, we did not detect expression in DG75 and Jurkat cells (Figure 8a) .
The mutations in MSH2 in lymphomas (Lowsky et al., 1997) were in exon 13 of the MSH2 gene and we sequenced MSH2 exon 13 from DG75 and Jurkat cells. We detected a point mutation (CGA4TGA) at codon 686 of MSH2 in Jurkat cells which would result in premature termination of translation (Figure 8b ). We did not detect mutations in MSH2 exon 13 of DG75 cells. Therefore, defects in MSH2 expression are likely to underlie MI of DG75 and Jurkat cells, and in the case of Jurkat cells, this is due to premature termination of translation. Consistent with this, Jurkat cell lysates were negative in assays for in vitro DNA repair, and this de®ciency could be complemented by cell lysates containing wild type MSH2 (pers. comm., O Humbert and P Karran). 
Discussion
In this paper we have examined BAX expression in cell lines derived from haemopoietic malignancies. Lymphoid hyperplasia in mice lacking Bax (Yin et al., 1994) suggested that BAX may function as a tumour suppressor in human haemopoietic cells. Consistent with a tumour suppressor role, we identi®ed two cell lines which lacked BAX expression due to frameshift mutations resulting in premature termination of translation. BAX mutations were associated with MI and resistance to apoptosis. These results suggest that a pathway linking MMR defects, the BAX tumour suppressor and resistance to apoptosis may be a key feature of some leukaemia and lymphoma.
MSH2 defects appeared to underlie the MI of DG75 and Jurkat cells. Interestingly, lack of MSH2 has been associated with haemopoietic malignancies as MSH2 defective mice are susceptible to lymphoid tumours (deWind et al., 1995; Reitmar et al., 1995) and MSH2 mutations have been identi®ed in exon 13 of MSH2 in human lymphomas (Lowsky et al., 1997) . MSH2 expression was not detectable in DG75 or Jurkat cells and, in this case of Jurkat cells, this was due to a mutation resulting in premature termination of translation. We did not detect mutations in DG75 cells, but to date we have only examined exon 13.
We detected expression of several BAX splice variant RNAs in addition to BAX a RNA. Interestingly, DG75 and Jurkat cells expressed relatively high levels of the BAX g and d RNAs, respectively. It is not clear whether this is a direct result of the BAX frameshift mutations in these lines on BAX splicing or, perhaps more likely, whether this re¯ects an indirect feedback loop which alters splicing in the BAX negative lines. Since BAX d RNA lacks exon 3 (Apte et al., 1995) which contains the (G)8 tract, its protein product should be wild type in Jurkat cells. However, we did not detect BAX d protein expression using antibody N-20 which recognises an epitope outside of exon 3. When we have attempted to overexpress BAX d in DG75 cells in transient transfections we either failed to detect expression or only detected very low level expression (data not shown). By contrast, BAX a overexpression was readily detectable in transient assays, suggesting that BAX d (and possibly other BAX isoforms such as BAX b) may be relatively unstable.
A critical question is whether the BAX frameshift mutations contribute to the malignant phenotype of the cells. BAX functions as a tumour suppressor in a murine model system by suppressing apoptosis (Yin et al., 1997) and two lines of evidence support the conclusion that BAX mutations we have identi®ed are important. First, of those regulators tested, only BAX expression correlated with the resistance to low serum or ionomycin. Moreover, downstream eector components of the apoptotic pathway were intact in DG75 cells since the delayed death of DG75 cells was due to apoptosis. Second, BAX missense mutations Figure 7 DG75 and Jurkat cells have microsatellite instability. DG75 and Jurkat cell genomic DNA, and DNA from normal individuals was analysed for instability at 35 microsatellite markers. Results for markers 2S340 and 22S315 are shown. Major peaks corresponding to individual alleles were identi®ed by computer analysis and the number of repeats for each peak is indicated. As expected, computer analysis identi®ed one or two alleles in normal controls (the minor bands are due to errors introduced during the ampli®ction reaction). In DG75 and Jurkat cells, computer analysis identi®ed 3 to 6 alleles, indicative of microsatellite instability have also been described in the Daudi BL and the HPB-ALL T cell leukaemia derived cell lines (Meijerink et al., 1995) . Although the functional signi®cance of these mutations has not been tested directly, in one case the mutation altered a highly conserved residue in the BH3 domain of BAX. BH3 is required for BCL-2 binding and induction of apoptosis (Zha et al., 1996) and BAX is likely to be functionally inactivated in these cells. Taken together, these observations suggest a pathway linking MMR defects, BAX tumour suppressor mutations and resistance to apoptosis is a key feature of some leukaemia and lymphoma and that loss of BAX function (by frameshift or missense mutations) plays a direct role in the development of some haemopoietic malignancies.
Materials and methods
Cell culture
BL41, DG75, Louckes, BL40 and BL2 are EBV negative BL derived cell lines. Akata, Elijah, Namalwa, Mutu III, Raji, BL72, BL74 and WeWakl are EBV positive BL derived cell lines. IB4 and X50-7 are EBV immortalized LCLs. Jurkat and CEM-C7 are T cell leukaemia derived cell lines, HUT78 is a T cell lymphoma derived cell line and H9 cells were derived from HUT78 (Gazdar et al., 1980) . U937 cells are derived from a histocytic lymphoma and K562 and ML-1 cells are derived from myeloid leukaemias. DG75 cells (Ben-Bassat et al., 1973) To induce BL cell apoptosis Henderson et al., 1991) , cells were ®rst cultured in RPMI-1640 medium that had been supplemented with 10% (v/v) serum supreme (Biowhittaker) and antibiotics. Cells were washed twice in RPMI-1640 and resuspended in RPMI-1640 supplemented with 0.1% serum supreme or with 10% serum with 2 mg/ml ionomycin (Sigma) at 0.25610 6 cells/ ml. Cell viability was determined by measuring trypan blue exclusion of duplicate cultures. Genomic DNA and cell morphology was analysed as previously described (Askew et al., 1991) .
Western blotting
For Western blotting, cells were collected by centrifugation and resuspended in RIPA (0.15 M NaCl, 1% (v/v) Nonidet P40 (NP40), 0.5% (v/v) sodium deoxycholate, 0.1% (w/v) sodium dodecylsulphate (SDS), 50 mM Tris-HCl pH 8.0 and protease inhibitors). After 5 min on ice, the lysates were clari®ed by centrifugation and supernatants collected. Protein concentration of a sample of the lysate was determined using the BioRad assay with bovine serum albumin as a standard. The remaining lysate was diluted with an equal volume of 26 protein sample buer (100 mM Tris-HCl pH 6.8, 4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) glycerol and 200 mM dithiothreitol) and proteins denatured by heating at 958C for 5 min. Equivalent amounts of cell lysates were resolved on SDS polyacrylamide gels and electrophoretically transferred to nitrocellulose. The ®lter was incubated in blocking buer (5% (w/v) dried non-fat milk in phosphate buered saline (PBS)) to block non-speci®c protein binding sites and antibody incubations were in binding buer (5% (w/v) dried non-fat milk in 150 mM NaCl, 10 mM Tris-HCl Jurkat genomic DNA was ampli®ed using primers Y3077 and Y3078 and subjected to direct sequencing using oligonucleotide Y3077 as a primer. The nucleotide sequence of MSH2 codons 682 to 690 and the predicted translation of wild type and mutant sequences is shown. The mutation was determined on both strands and also in cloned PCR products pH 8.0 (TS buer)). After each antibody incubation, the ®lters were washed twice in TS and twice in TST (TS buer supplemented with 0.05% (v/v) Tween). Bound immunocomplexes were detected by enhanced chemiluminescence (Amersham) and luminography. BAX expression was quantitated using a GS300 scanning densitometer (Hoefer). The BAX speci®c antibody N-20 (Santa Cruz Biotechnology, Inc.) recognises an epitope contained within amino-acid residues 2 ± 21 of human BAX and was used at a ®nal concentration of 0.5 mg/ml. The BAX speci®c antibody 13666E (Pharmingen) recognises an epitope contained within amino acid residues 43 ± 61 of human BAX and was used at a ®nal dilution of 1 : 1000. The BCL-X speci®c antibody S-18 (Santa Cruz Biotechnology, Inc.) was used at a ®nal concentration of 0.4 mg/ml. The MSH2 speci®c antibody Ab-3 (Oncogene Science) was used at a ®nal concentration of 1 mg/ml. The ®nal antibodies were a horse radish peroxidase (HRP) conjugated donkey anti-rabbit immunoglobulin (Ig) antibody or an HRP-conjugated sheep anti-mouse Ig antibody (both Amersham).
RNAse protection assay
To generate probe A, plasmid phb2 (a kind gift of Dr S Apte, Apte et al., 1995) which contains the BAX a cDNA was digested with EcoRI (which cuts in the polylinker 5' of the BAX ATG) and PstI (which cuts at BAX a coding nucleotide 230). The smaller fragment was isolated and cloned into Bluescript KS(7) that had been digested with the same enzymes. The resultant plasmid was linearized with EcoRI and probe A generated using T7 RNA polymerase. To generate probe B, plasmid phb2 was digested with BamHI (which cuts in the polylinker 5' of the BAX ATG and at BAX a coding nucleotide 452). The smaller fragment was isolated and cloned into Bluescript KS(7) which had been digested with BamHI with the BAX ATG closest to the T3 promoter. The resultant plasmid was linearized with PstI (which cuts at BAX coding nucleotide 230) and probe B generated using T7 RNA polymerase.
RPAs were performed using total RNA and the RPA II kit (Ambion) according to the manufacturer's instructions. Brie¯y, equivalent amounts of RNA (40 mg) were precipitated with riboprobe (25 000 cherenkov c.p.m.). Yeast total RNA was used as a negative control. The RNA/probe was resuspended in 20 ml of hybridization solution and incubated overnight at 428C. Unprotected probe was removed by digestion with RNase A/T1 and protected fragments resolved on a denaturing polyacrylamide gel.
RT ± PCR
To analyse BAX RNAs by RT ± PCR, total RNA isolated from DG75, Jurkat, IB4 and Namalwa cells was converted to cDNA. A portion of the cDNA reaction was then ampli®ed in a polymerase chain reaction using primers T4581 (GGAGAATTCGTGATGGACGGGTCCGGG-GAGCAGCCCAGAGGC) and T4580 (GCAGCGTC-GACCTCAGCCCATCTTCTTCCAGATGGTGAGCGA). The PCR parameters were 948C for 2 min, followed by ®ve cycles of 928C, 30 s; 458C, 90 s; 728C, 2 min, 25 cycles of 928C, 30 s; 508C, 90 s; 728C 2 min and then 5 min at 728C. The PCR products were resolved on a 2% agarose gel, transferred to nitrocellulose and analysed by hybridization using 32 P-labeled BAX a coding sequence as a probe.
PCR analysis of BAX and MSH2 exon 13
To analyse the BAX G(8) tract, genomic DNA was prepared from DG75, Jurkat and Namalwa cells and ampli®ed in a PCR reaction using primers W5584 (ATCCAGGATCGAGCAGGGCG) and W5585 (ACTC-GCTCAGCTTCTTGGTG) using Pfu DNA polymerase (New England Biolabs, Inc.) in the presence of [ 32 P] dCTP, as previously described (Rampino et al., 1997) . The products were analysed on a 6% denturing polyacrylamide gel. PCR products obtained using DG75 and Jurkat DNA without [
32 P] dCTP were subcloned and the sequence surrounding the (G)8 tract was determined by double stranded DNA sequencing.
To sequence MSH2 exon 13, genomic DNA from Jurkat and DG75 cells was ampli®ed using primers Y3077 (GGACAGAGACATACATTTCTATC) and Y3078 (CGCGATTAATCATCAGTG) and the product sequenced directly as previously described (Lowsky et al., 1997) .
Microsatellite instability
DG75 and Jurkat genomic DNA was analysed for instability at 35 microsatellite markers. Because DNA from non-neoplastic cells from the same individual was not available, DNA prepared from peripheral blood of normal individuals was analysed as a control. PCR was performed using one¯uorescent labelled primer and PCR products were analysed using an ABI 377 DNA sequencer and GeneScan and Genotype software.
